



ASX ANNOUNCEMENT

CLEANSING NOTICE

Perth, Australia; 11 November 2020. NeuroScientific Biopharmaceuticals Ltd ASX: NSB ("NeuroScientific" or "the **Company**") gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) that:

1. Pursuant to a private placement announced by the Company on 11 November 2020 (The **Placement**), the Company has agreed to issue:
 - a. 8,571,429 fully paid ordinary shares to an unrelated sophisticated investor, at an issue price of \$0.28 per share, to raise \$2,400,000 (before costs) in proceeds; and
 - b. A total of 1,600,000 unlisted options to Westar Capital Limited in consideration for their role as Lead Manager. The options have an exercise price of \$0.45 each and an expiry date of 2 years from date of issue.

All shares will be issued under the Company's Listing Rule 7.1 placement capacity.

2. The shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
3. As at the date of this notice:
 - a. the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company;
 - b. the Company has complied with section 674 of the Corporations Act; and
 - c. the Company is not in possession of any undisclosed "excluded information" within the meaning given to that term in sections 708A(7) and (8) of the Corporations Act, which is required to be disclosed under section 708A(5)(e) of the Corporations Act.

END

Announcement authorised by the Board of Directors of NeuroScientific Biopharmaceuticals

Contacts

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+61 8 6382 1805

Brian Leedman
Non-executive Chairman
bl@neuroscientific.com
+61 412 281 780